Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 22(4): 1161-1167, 2018 02.
Article in English | MEDLINE | ID: mdl-29509270

ABSTRACT

This review illustrates some brief considerations of the medical use of cannabis recently issued in Italy. History and uses of cannabis throughout centuries and different countries are illustrated together with a description of botany and active phytocannabinoids. Then, medical use of cannabis anti-pain treatment for patients resistant to conventional therapies is described in case of chronic neuropathic pain, spasticity, for anticinetosic and antiemetic effect in nausea and vomiting caused by chemotherapy, for appetite stimulating effect in cachexia, anorexia, loss of appetite in cancer patients or patients with AIDS and in anorexia nervosa, hypotensive effect in glaucoma resistant to conventional therapies and for reduction of involuntary body and facial movements in Gilles de la Tourette syndrome. Italian most recent legislation on medical cannabis is detailed with some law proposals, also showing the inconsistent legislation within European Union. Some final considerations of future studies are also reported.


Subject(s)
Legislation, Drug/trends , Medical Marijuana/therapeutic use , Pain Management/trends , Antiemetics/therapeutic use , Cachexia/drug therapy , Cachexia/epidemiology , Europe/epidemiology , Humans , Italy/epidemiology , Muscle Spasticity/drug therapy , Muscle Spasticity/epidemiology , Nausea/drug therapy , Nausea/epidemiology , Neoplasms/drug therapy , Neoplasms/epidemiology , Neuralgia/drug therapy , Neuralgia/epidemiology , Pain Management/methods , Tourette Syndrome/drug therapy , Vomiting/drug therapy , Vomiting/epidemiology
2.
Eur Rev Med Pharmacol Sci ; 21(1 Suppl): 46-52, 2017 03.
Article in English | MEDLINE | ID: mdl-28379595

ABSTRACT

The available literature assessing Chelidonium majus L. (CM) hepatotoxicity potential, and its risk to benefit assessment has been reviewed in this paper. Identification of significant scientific literature was performed via the following research databases: Cochrane Central, Google Scholar, EMBASE, Medline, Science Direct, Scopus, Web of Science, using the following keywords: "Chelidonium majus", "greater celandine", "Hepatotoxicity", "Liver" "Injury", "Toxicity" individually investigated and then again in association. CM named also greater celandine, swallow-wort, or bai-qu-cai (Chinese), has been used for a long time in traditional Chinese medicine and phytotherapy. Its extracts have been claimed to display a wide variety of biological activities: antimicrobial, anti-inflammatory, spasmolytic, antineoplastic, hepatoprotective, and analgesic. Moreover, herbal medicine suggests this plant have numerous additional effects which have not yet been scientifically evaluated, such as antitussive, diuretic, and eye-regenerative. However, despite its claimed hepatoprotective effects, several hepatotoxicity cases have been reported to be probably or highly probably connected with CM exposure, after their evaluation through liver-targeted causality assessment methods. CM hepatotoxicity has been defined as a distinct form of herb-induced liver injury (HILI), due to an idiosyncratic reaction of the metabolic type. This evidence has to be considered in relationship with the absence of considerable benefits of CM therapy. Therefore, the risk to benefit ratio of the use of herbal products containing greater celandine can actually be considered as negative.


Subject(s)
Chelidonium , Chemical and Drug Induced Liver Injury , Phytotherapy , Humans , Liver/drug effects , Parasympatholytics/pharmacology , Plants, Medicinal
SELECTION OF CITATIONS
SEARCH DETAIL